Bad Stats Plague Neuroscience

A new study blames the unreliable nature of some research in the field on underpowered statistical analyses.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

An image from an fMRI study of brain activity in schizophrenia patientsWIKIMEDIA, PLOS One. 2010 AUG 11;5(8):e12068.Weak statistics are the downfall of many neuroscience studies, according to researchers that analyzed the statistical strategies employed by dozens of published reports in the field. Especially lacking in statistical power are human neuroimaging studies—especially those that use fMRI to infer brain activity—noted the coauthors of the analysis, published in Nature Reviews Neuroscience last week (April 10).

By taking a look at 49 meta-analyses published in 2011, involving a total of 730 neuroscience studies, a team of researchers from the United Kingdom and United States found that about half of the papers had a statistical power below 20 percent. Statistical power is a measure of the probability that a study will detect the presence of a true phenomenon in the samples at hand. High-powered studies can demonstrate even small effects if sample sizes are big enough. Low-powered studies, however, run the risk of either missing genuine phenomena or reporting false positives, usually due to considering too few samples. Research studies typically aim to have a statistical power of at least 80 percent.

Human neuroimaging studies had a median statistical power of just ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies